UNLABELLED: Plasmodium vivax (Pv) malaria is being increasingly recognized as a cause of severe malaria in children. OBJECTIVES: To describe the various severe manifestations associated with vivax malaria by retrospective analysis of records. METHODS: Children between the ages of 0 and 18 years with a confirmed diagnosis of Pv malaria monoinfection done by peripheral blood film (PBF) and/or rapid diagnostic test (RDT) admitted between June and September 2009 were included. Their clinical, hematological and biochemical manifestations were analyzed. RESULTS: Twenty-three patients of Pv malaria were retrospectively analyzed. Thrombocytopenia was present in 22 (96%) patients with counts less than 50,000/ μL in 9 patients. Severe anemia (hgb<5mg/dl) was present in 8 (34%) patients. Cerebral malaria was present in 3 patients. Liver enzymes were elevated (>3 times normal) in 4 (17.3%) patients while jaundice (bilirubin>2.5mg/dl) was present in 2 patients (total bilirubin 5.2mg/dl and 14.3mg/dl). Renal dysfunction (creatinine>3mg/dl) was present in 6 (26%) patients with 2 patients showing severely deranged renal functions (blood urea 168 mg/dl, 222 mg/dl and serum creatinine 5.0mg/dl, 5.6 mg/dl, respectively). Hypernatremia was present in one patient. One patient expired within 12h of presentation because of severely deranged hepatic and renal dysfunction. CONCLUSION: Pv malaria can lead to unusual and fatal complications. All new guidelines should include "Severe Vivax malaria" as a clinical entity. Further research into the etiopathogenesis and treatment would be important.
UNLABELLED: Plasmodium vivax (Pv) malaria is being increasingly recognized as a cause of severe malaria in children. OBJECTIVES: To describe the various severe manifestations associated with vivax malaria by retrospective analysis of records. METHODS:Children between the ages of 0 and 18 years with a confirmed diagnosis of Pvmalaria monoinfection done by peripheral blood film (PBF) and/or rapid diagnostic test (RDT) admitted between June and September 2009 were included. Their clinical, hematological and biochemical manifestations were analyzed. RESULTS: Twenty-three patients of Pvmalaria were retrospectively analyzed. Thrombocytopenia was present in 22 (96%) patients with counts less than 50,000/ μL in 9 patients. Severe anemia (hgb<5mg/dl) was present in 8 (34%) patients. Cerebral malaria was present in 3 patients. Liver enzymes were elevated (>3 times normal) in 4 (17.3%) patients while jaundice (bilirubin>2.5mg/dl) was present in 2 patients (total bilirubin 5.2mg/dl and 14.3mg/dl). Renal dysfunction (creatinine>3mg/dl) was present in 6 (26%) patients with 2 patients showing severely deranged renal functions (blood urea 168 mg/dl, 222 mg/dl and serum creatinine 5.0mg/dl, 5.6 mg/dl, respectively). Hypernatremia was present in one patient. One patient expired within 12h of presentation because of severely deranged hepatic and renal dysfunction. CONCLUSION:Pvmalaria can lead to unusual and fatal complications. All new guidelines should include "Severe Vivax malaria" as a clinical entity. Further research into the etiopathogenesis and treatment would be important.
Authors: Vivek B Kute; Aruna V Vanikar; Pramod P Ghuge; Jitendra G Goswami; Mohan P Patel; Himanshu V Patel; Manoj R Gumber; Pankaj R Shah; Hargovind L Trivedi Journal: Parasitol Res Date: 2012-06-06 Impact factor: 2.289
Authors: Vivek B Kute; Jitendra G Goswami; Aruna V Vanikar; Pankaj R Shah; Manoj R Gumber; Himanshu V Patel; Kamal V Kanodia; Hargovind L Trivedi Journal: Parasitol Res Date: 2011-12-29 Impact factor: 2.289
Authors: Fernando Val; Kim Machado; Lisiane Barbosa; Jorge Luis Salinas; André Machado Siqueira; Maria Graças Costa Alecrim; Hernando Del Portillo; Quique Bassat; Wuelton Marcelo Monteiro; Marcus Vinícius Guimarães Lacerda Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345